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The failure of large-scale drug trials targeting the amyloidogenic pathway in Alzheimer’s disease 
(AD) is increasing the need to identify a novel pathogenic mechanism. Studies finding a relation-
ship between sporadic AD and type-2 diabetes mellitus (T2DM) are now receiving more atten-
tion. The risk for developing both T2DM and sporadic AD increases exponentially with age, and 
having T2DM doubles the risk of developing AD. The postmortem brains of AD patients show 
altered activities of insulin receptors and downstream molecules, as well as reduced protein and 
mRNA levels of insulin. More-recent laboratory research using animal models has identified 
mechanisms that are shared by diabetes and AD. Exogenous application of streptozotocin, which 
disrupts systemic insulin secretion, results in insulin deficiency, increased tau phosphorylation, 
and cognitive impairments that can be reversed by exogenous insulin supplementation. Howev-
er, AD pathology is more severe in T2DM animal models exhibiting hyperinsulinemia and insu-
lin resistance, and this is not modulated by insulin. The symptoms of this AD pathology included 
increased tau phosphorylation at multiple sites, increased tau cleavage, and greater neuronal and 
synaptic damage, even with increased amyloid β protein production. It has therefore been sug-
gested that hyperinsulinemia and insulin resistance represent major factors underlying AD in 
T2DM. A recent study involving cross-mating ob/ob and amyloid precursor protein transgenic 
mice provided evidence that T2DM and AD aggravate each other, and suggested that cerebral 
vessels constitute an important substrate that is commonly damaged by the two major disorders. 
Given the evidence provided by animal models, further investigation of the mechanisms underly-
ing T2DM in AD should help to identify potential treatment targets in AD.   
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Introduction
Alzheimer’s disease (AD), which is the most-prevalent neuro-
degenerative disease, results in progressive cognitive dysfunc-
tion and inability to perform complex daily activities. As a re-
sult of the incapacity experienced by those with AD, a huge 
burden is inevitably placed on caregivers, which makes AD a 
major social problem.
1 There is strong evidence from genetic 
studies of familial AD that amyloid β proteins, which are pro-
duced by sequential cleavages of amyloid precursor proteins 
(APPs) by the β-site of the APP-cleaving enzyme (BACE), fol-
lowed by γ-secretase, play central roles in AD.
2 There have been 
repeated tests of therapeutic strategies directly targeting Aβ 
production, such as inhibiting or modulating BACE and γ- 
secretase, using aggregation blockers, clearance-enhancing, 
and vaccinating with Aβ peptides or antibodies against vari-
ous Aβ epitopes.
3 However, in contrast to the results obtained 
by studies on transgenic animals with familial AD mutation, 
no evidence of the efficacy of these approaches has been 
produced in human AD patients.
4 Therefore, it is highly likely 
that familial and sporadic AD are characterized by different ty-
pes of pathogenesis.
Several studies have produced epidemiological, clinical, 
and pathological evidence of the relationship between AD and 
type-2 diabetes mellitus (T2DM). Longitudinal epidemiologi-
cal studies have revealed that the risk of developing late-onset 
AD is 1.4-4.3 higher among those with T2DM,
5-10 and that AD 
patients showed elevated plasma but lower cerebrospinal fluid 
(CSF) insulin levels, disrupting the relationship between pe-
ripheral and central insulin.
11 Furthermore, the postmortem Park SA
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brains of individuals who had been diagnosed with AD showed 
decreased insulin, insulin-like growth factor 1 (IGF-1), and re-
ceptor activities in proportion to the severity of disease.
12 This 
relationship was greater in the elderly and in non-apolipopro-
tein-E4 carriers.
11 Therefore, the mechanism linking T2DM 
and AD is expected to provide an important clue toward eluci-
dating the process underlying sporadic AD, especially in those 
AD patients not carrying the known major risk factor for spo-
radic AD, apolipoprotein-E4. This paper reviews the evidence 
of the close relationship between T2DM and AD obtained by 
various animal studies, and summarize the proposed pathogen-
ic mechanism shared by these two major disorders.
Studies in Diabetes 
Mellitus Models (Table 1)
Streptozotocin-injection model
Streptozotocin [STZ; 2-deoxy-2-(3-(methyl-3-nitrosoureido))-
D-glucopyranose], a betacytotoxic drug, selectively destroys 
insulin-secreting pancreatic β cells and thereby causes type-1 
diabetes mellitus (T1DM).
13 Although the STZ-injection mu-
rine model has been the most-widely used to investigate the re-
lationship between diabetes mellitus (DM) and AD, studies re-
lying on this model have focused on T1DM, which has pro-
duced less evidence of a relationship with AD than has T2DM. 
Nonetheless, increased tau phosphorylation with decreased 
binding to microtubules has been noted consistently in research 
using the STZ-injection murine model;14-16 this result has prob-
ably been due to inhibited phosphatase activities rather than to 
enhanced kinase activities.
14 This effect was substantially re-
versed by supplying insulin. However, contradictory results have 
emerged with respect to Aβ pathology.
STZ itself cannot pass through the blood-brain barrier due to 
the absence of the STZ transporter GLUT2. Therefore, the sys-
temic-injection model can reveal only the effect of systemic 
hypoinsulinemia on the brain. Direct injection of STZ into the 
brain has thus been attempted.
Inside the mammalian brain, GLUT2 is distributed heteroge-
neously;17 therefore, intracerebroventricular (i.c.v.) injection of 
STZ can selectively decrease the level of insulin in the brain 
without disturbing systemic insulin and glucose levels. In ad-
dition, the expression levels of insulin and IGF-1 receptors were 
reduced, showing that insulin signaling was impaired,
18,19 which 
is similar to the condition observed in the postmortem brains of 
AD patients with so-called type-3 diabetes,
20 characterized by 
simultaneously decreased insulin production and resistance to 
insulin reception in the brain. Although increased phosphoryla-
tion of tau was noted consistently after i.c.v. injection of STZ, 
this phenomenon was present at more sites, inhibiting micro-
tubule-binding activities. Overactivation of glycogen synthase 
kinase-3β (GSK3β) and decreased O-linked N-acetylglucos-
amine glycosylation (O-GlcNAcylation) resulting from im-
paired insulin signaling have been found to be the primary 
causes of hyperphosphorylation of tau. In relation to Aβ pathol-
ogy, the change in brain parenchyma was subtle, but increased 
Congo-red-positive aggregates were observed in brain capillar-
ies, suggesting that Aβ-related impairment of the microcircula-
tion is present in this animal model.
In summary, increased tau phosphorylation and microtubule 
instability resulting from decreased phosphatase activity has 
been noted consistently in studies using the STZ-injection mod-
el, with these consequences being reversed by exogenous insu-
lin supplementation. Significant Aβ pathology was not observed 
on the basis of this systemic insulin-deficient model, suggest-
ing that insulin deficiency itself is not sufficient for the emergen-
ce of AD. On the other hand, i.c.v. STZ-injected subjects who 
experience problems with both insulin production and insulin 
signaling similar to those seen in the brains of animals with AD 
demonstrated more-extensive tau and Aβ-related pathology in 
microvessels. Thus, insulin resistance is thought to be an impor-
tant contributor to the emergence of AD pathology in DM.
The spontaneous DM model
The spontaneous DM model may be more suitable for validat-
ing the relationship between DM and AD pathology since al-
lowing a subject’s experience to progress from the preclinical 
to the fully developed stage more closely replicates the prog-
ress of actual patients. Several different spontaneous DM mod-
els have been developed through specialized in-breeding. BB/
Wor rats represent the T1DM model, in which autoimmune pro-
blems destroy insulin-secreting β cells in the pancreas. Cogni-
tive dysfunction, along with typical neurodegenerative chang-
es such as gliosis and neuronal and synaptic loss, have been 
noted in studies using this approach.
21 In relation to AD pathol-
ogy, increased tau phosphorylation as well as increased APP, 
BACE, and amyloid β proteins were present in this rodent 
model. All of this pathology was reversible by the application 
of insulinomimetic C-peptide, suggesting that insulin deficien-
cy is the major mechanism underlying AD-related pathology 
in this model. 
However, there was much less pathology in this model than 
in Bio-Breeding Zucker diabetic rat/Wor rats, which is a T2DM 
spontaneous model that was evaluated at the same time.
21 AD 
pathology has been evaluated extensively in two widely avail-
able T2DM spontaneous models: Bio-Breeding Zucker dia-
betic rat/Wor rats and db/db mice.
14,21 It was found that the 
neurodegenerative changes, consisting of neuronal loss, glio-
sis, and synaptic loss, were more prominent in these models. In 
addition, the diabetes-associated increase in tau phosphorylation 
was noted to be more widespread and more extensive than in Type2 Diabetes and AD
12  J Clin Neurol 2011;7:10-18
the T1DM model. Interestingly, increased tau cleavage, which 
is known to be particularly toxic to neurons and to form a nu-
cleation for neurofibrillary tangles,
22 occurred exclusively 
with the T2DM model.
14
From the greater AD pathology in the T2DM model it can be 
suggested that an important pathogenic factor intimately relat-
ed to T2DM plays a critical role in AD pathology and that in-
vestigation into this factor will provide important clues as to 
the identity of the mechanism responsible for sporadic AD. 
T2DM is characterized by insulin resistance and consequent 
Table 1. Animal studies using the diabetes mellitus model in the literature
Animal model AD pathology Behavior outcome
STZ-injection model
STZ systemic injection  
  to C57BL/6J, JAX mice14
↑Tau phosphorylation at S199/202, T231
No tau cleavage
*  But less-prominent tau pathology than T2DM model, db/db 
  mice compared at the same time
ND
STZ systemic injection to Swiss  
  Webster mice16
↑Tau phosphorylation at T231
↑Aβ, but similar level of APP and CTF
Partial reversal of the changes by insulin
Impaired learning on  
  Barnes circular-maze task
STZ systemic injection  
  to C57BL/6NJcl mice15
↑  Tau phosphorylation at the S199, S396, S404 (prevented 
  by supplement of insulin)
→↓Tau binding to microtubules,
p-tau is limited to the neuropil and axons,
But, no difference in APP, CTF, and Aβ levels
ND
STZ i.c.v. injection  
  to Wistar rats19
↑  Tau phosphorylation at S199, T212, S396 in the cerebrum,  
  but not at S202, T205, S214, S217, S262, S422
↑Phosphorylation of neurofilaments
↓Microtubule-binding activity of tau
↑Neurofibrillary degeneration
ND
STZ i.c.v. injection  
  to Wistar rats18
↑   Congo-red-positive aggregates in the brain capillaries,  
  suggesting Aβ peptide-like aggregates
↓Memory function  
  on Morris water-maze test
Spontaneous DM model
BBZDR/Wor rats, T2DM model  
  compared with BB/WOR,  
  T1DM model21
Neuronal loss in both, but worse in BBZDR/Wor
Gliosis in both, but more in BBZDR
↓Synaptophysin stain
↑Dystrophic neuritis, but worse in BBZDR
↑APP, BACE, β-amyloid, but more in BBZDR
↑Tau phosphorylation in both, but more in BBZDR
ND
db/db mice (T2DM) compared 
  with STZ-injection model14
↑Tau cleavage
↑   More prominent tau phosphorylation at more sites,  
  S199/202, T231, and Ser396, compared with STZ
ND
Genetically engineered model targeting insulin signaling
Neuron-specific insulin  
  receptor KO mice24
Complete loss of activation of PI-3K
Markedly decreased p-Akt and p-GSK3β
↑Tau phosphorylation at T231 but not at S202
No alteration in neuronal proliferation/survival
No memory impairments
No change in brain  
  glucose metabolism  
  on PET
IRS-2-deletion mice25 ↓  Neuronal proliferation during development by 50%,  
  but not increased apoptosis
↑Tau phosphorylation at S202 in cytoplasmic deposits
ND
Double Tg2576/Irs2–/– mice26 ↓Amyloid deposition
but ↑tau phosphorylation (at S409, S396/404, S235, S202) 
  with reduced tau phosphatase PP2A
Improved  
  behavioral deficits 
IDE-KO mice27 >50% decrease in Aβ degradation
↑Cerebral accumulation of endogenous Aβ
ND
*T2DM model was evaluated and compared at the same time. 
Aβ: amyloid β protein, AD: Alzheimer’s disease, APP: amyloid precursor protein, BACE: β-site of the APP-cleaving enzyme, BBZDR: bio-breed-
ing zucker diabetic rat, CTF: c-terminal fragment, i.c.v.: intracerebroventricular, DM: diabetes mellitus, IDE: insulin-degrading enzyme, IRS-
2: insulin receptor substrate 2, KO: knockout, ND: no test for cognition or behavior, PET: positron-emission tomography, p-GSK-3β: phos-
phorylated glycogen synthase kinase-3β, PI-3K: phosphatidylinositol 3-kinase, PP2A: protein phosphatase 2A, p-tau: phosphorylated tau, 
STZ: streptozotocin, T1DM: type-1 DM, T2DM: type-2 DM, Tg: transgenic.Park SA
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impaired glucose metabolism and utilization. The reduced abil-
ity of insulin receptors to respond to insulin characterizes the 
insulin resistance suffered by most AD patients.
23 For this rea-
son, insulin signaling has been the prime target of investigations 
into the factors linking T2DM and AD.
Genetically	engineered	model	targeting	insulin	signaling
Studies performed using genetically modified animals and tar-
geting insulin signaling have attempted to identify the steps in-
volved in insulin signaling that have the greatest relevance for 
AD pathology.
24-26
Neuron-specific insulin receptor knockout mice
24
A mouse with selectively deficient insulin receptors in the brain 
shows complete inhibition of phosphatidylinositol 3-kinase 
(PI-3K) and dramatic inhibition of downstream Akt molecules. 
Blocking Akt activation is expected to decrease the phosphor-
ylation of GSK3β, thereby inducing the phosphorylation of 
tau.
24 However, the patterns of tau phosphorylation differ with 
the location of the phosphorylation characterized by the decre-
ase at Thr231 and the increase at Ser201, even though both sites 
have been reported to be GSK3β substrates. Moreover, there is 
as yet no evidence of neuronal cell damage, cognitive dysfunc-
tion on the Morris water-maze test, or changes in glucose me-
tabolism as detected on positron-emission tomography (PET) 
scans, which strongly suggests that the abolition of insulin re-
ceptors does not significantly affect AD pathology.
Insulin-receptor-substrate-2-knockout mice
Insulin receptor substrate (IRS) is the molecule connecting the 
receptors for insulin and IGF-1 to various downstream effec-
tors including PI-3K, Akt, and extracellular signal-regulated ki-
nase cascades. Consistent with other experiments conducted 
using DM models, studies of IRS-2
-/-mice have shown highly 
increased phosphorylation of tau, but no disturbance of neuro-
nal survival and gliosis.
25 The questionable effect of IRS-2 on 
AD pathology was also demonstrated in a study of Tg2576/
IRS-2
-/-, which was conducted by cross-mating the IRS-2 dele-
tion model with Tg2576, the APPswe-overexpressing AD 
model.
26 Contrary to expectations, IRS-2 deletion significant-
ly decreased the Aβ burden and improved cognitive function-
ing. However, increased tau phosphorylation at 396/404, 235, 
and 231 without the formation of tangles was also noted. The 
clear dissociation of tau pathology from Aβ pathology and cog-
nition clearly shows that increased tau phosphorylation per se 
is not the critical factor linking T2DM and AD. Together the 
findings obtained using different spontaneous T2DM models 
show that specific ablation of individual steps of insulin signal-
ing does not result in evident AD pathology, which suggests 
that simple impairment of the insulin signaling does not play 
an important role in AD pathology.
Insulin degradation enzyme knockout mice
Insulin degradation enzyme (IDE) is the major enzyme in-
volved in insulin destruction through a direct interaction. It is 
also known to play a critical role in Aβ clearance.
27 Its affinity 
for insulin is higher than for Aβ; therefore, more IDE tends to 
bind to insulin in the milieu of hyperinsulinemia, actually re-
sulting in decreased Aβ degradation. A study using IDE-defi-
cient mice clearly demonstrated the potent regulating effect of 
IDE on Aβ metabolism. Indeed, the level of cerebral Aβ in-
creased by 10-65% in IDE
-/- mice.
27 Furthermore, IDE degrad-
ed primarily to soluble Aβ, the most-neurotoxic form of Aβ.
28 
Thus, the relative shortage of usable IDE as a result of the hy-
perinsulinemia associated with T2DM and the consequent in-
crease in soluble Aβ may play central roles in the linkage be-
tween T2DM and AD.
Studies with Alzheimer’s Disease 
Models (Table 2)
In addition to the aforementioned investigations involving on 
DM animal models, an increasing number of recent studies of 
the significance of the concurrent pathologies of DM and AD 
and their common mechanisms have relied on AD models that 
include diabetes. A review of recent well-designed studies us-
ing AD models enables understanding of the current status and 
future directions of research in this domain.
The effect of STZ injection in the transgenic 
mouse model of AD
The effects of DM as a result of systemic-STZ-induced insulin 
deficiency were evaluated in two transgenic models: pR5 mice 
with P301L tau and triple transgenic (3xTG) AD.
29,30 Aggrava-
tion of tau pathology by concomitant DM was evident, with 
markedly increased phosphorylation and insoluble fraction of 
tau forming neurofibrillary tangles.
29 The same effect of DM 
on APP and soluble Aβ was also noted, but not on the expres-
sion of total tau in the 3xTG AD model.
30 Interestingly the am-
yloidogenic effect of DM was decreased by continuous sup-
plementation of a glucagon-like peptide-1 agonist, one of the 
antidiabetic medications.
As described above, i.c.v. injection of STZ results in an insulin-
resistant state in the brain.
18,19 Therefore, this model is useful for 
evaluating the effect of insulin resistance. Reduced cognition as 
well as increased cerebral aggregated Aβ fragments, total tau 
proteins, and congophilic amyloid deposits were observed when 
Tg2576 mice injected with STZ at 3 months of age were evalu-
ated at 9 months of age.
31 Thus, both insulin deficiency and in-
sulin resistance are thought to accelerate AD pathology.Type2 Diabetes and AD
14  J Clin Neurol 2011;7:10-18
AD	model	with	a	high-fat	diet
32-34
The ingestion of a high-fat diet over a long period leads to in-
sulin resistance and obesity, which are core findings of T2DM. 
Functional abnormalities in insulin signaling, such as decreased 
insulin receptor β subunit autophosphorylation and reduced PI-
3K-Akt signaling, are evident in this line of research. Feeding 
Tg2576 (APPswe-overexpressing) mice a high-fat diet for sev-
eral months induced increased Aβ generation, Aβ plaque bur-
den, and γ-secretase activity, with decreased IDE activities.
32,33 
Decreased phosphorylation of GSK-3α and GSK-3β, which in-
crease tau phosphorylation, was found, and the extent of this de-
crease was strongly correlated with the levels of γ-C-terminal 
fragment. In addition, impaired behavioral performance ac-
companied this pathologic abnormality. The aggravating effect 
of T2DM on AD pathology via ingestion of a high-fat diet was 
reinforced by a study using 3xTG AD mice,
34 which showed in-
creases in Aβ40, Aβ42, and soluble tau.
Cross-mated	double-transgenic	models	of	AD	and	DM
Recent data obtained from cross-mated double-transgenic an-
imals with APP23-ob/ob and APP23-NSY mice show the im-
pact of T2DM on AD pathology, providing evidence of dif-
ferent pathogenic mechanisms.
35 APP23 is a well-established 
AD model that overexpresses the Swedish mutation form of 
APP with a Thy-1 promoter. An ob/ob mouse is leptin deficient, 
and an NSY mouse is a polygenic T2DM model.
36 Double-
transgenic mice exhibited an earlier onset of diabetes and more-
severe cognitive impairment. Interestingly, prominent micro-
vascular changes, characterized by increased inflammation 
with up-regulated receptors for advanced glycation end prod-
ucts (RAGE) expression and amyloidosis, were prominent in 
these brains, and these signs correlated strongly with other neu-
ropathological changes such as reactive gliosis and decreased 
cholinergic fibers. However, no increase in brain Aβ levels was 
observed. Consistent findings have been found in studies of 
APP23-NSY animals fed a high-fat diet; these include remark-
able vascular inflammation with amyloidosis in the absence of 
an altered Aβ burden in the brain. RAGE are known mediate the 
pro-oxidant effects precipitated by Aβ acting on neuronal and 
cerebrovascular cells in the context of AD.
37 Given the early and 
marked increase in RAGE expression combined with the Aβ 
found in microvessels, RAGE-Aβ interactions in small cerebral 
vessels probably play major roles in the pathogenesis linking 
T2DM and AD when both disorders are present.
Table 2. Animal studies using an AD transgenic animal model in the literature
Animal model AD pathology Behavior outcome
STZ systemic injection to AD TG model
STZ systemic injection to pR5  
  mice (P301L tau)29
Aggravation of tau pathology by DM; ↑tau phosphorylation,  
  ↑Insoluble tau, ↑neurofibrillary tangle (pR5 with STZ > pR5 without STZ) 
ND
STZ systemic injection to 3xTG  
  AD mice30
↑Soluble Aβ and APP, but no change in total tau ND
i.c.v. STZ injection into AD TG model
STZ i.c.v. injection to TG2576  
  (APP695swe)31
↑Level of Aβ and diffuse Aβ plaques
↑Total tau, ↑total GSK3α/β, but normal p-tau
↓Phosphorylated/total GSK3α/β ratio
A linear negative correlation between Aβ42 and cognition, and  
  between GSK3 α/β ratio (phosphorylated/total)
↓Spatial memory,
↓Spatial cognitive perfor- 
  mance
High-fat diet in AD TG model
In TG257633 ↑Aβ generation, ↑Aβ plaque burden, and ↑γ-secretase activity
↓Phosphorylation of GSK3α and -β
Impaired spatial learning
In 3xTG AD mice34 ↑Aβ40 and Aβ42 in detergent-insoluble extracts
↑Soluble tau
↓Postsynaptic marker, drebrin
Cross-mated double-transgenic models of AD and DM
APP23–ob/ob by cross-mating 
  and APP23-NSY by pronuclear  
  microinjection35
↓Brain weight of APP–ob/ob, ↑inflammatory molecules, IL-6, TNF-a
↑Astrogliosis, ↓CHAT-immunoreactive fibers
Dense amyloid deposits in small arteries of APP–ob/ob,
but only faint amyloid plaques in entorhinal cortex of APP  
  or APP–ob/ob
Early markedly increased RAGE immunoreactivity in blood vessels  
  of APP–ob/ob
Early learning deficit
Poor performance  
  in visible-platform test
Aβ: amyloid β protein, AD: Alzheimer’s disease, APP: amyloid precursor protein, CHAT: choline acetyltransferase, DM: diabetes mellitus, 
i.c.v.: intracerebroventricular, IL: interleukin, ND: no test for cognition or behavior, p-tau: phosphorylated tau, RAGE: receptor for advanced 
glycation end products, STZ: streptozotocin, Tg: transgenic, TNF-a: tumor necrosis factor alpha, 3xTG: triple transgenic.Park SA
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Potential mechanisms linking T2DM and AD
Data from animal studies illustrating the intimate relationship 
between T2DM and AD provide insights into the mechanisms 
shared by these conditions. This section summarizes the mech-
anisms shared by T2DM and AD (Table 3), which were initial-
ly suspected to be epiphenomenal but are now considered to 
constitute the molecular mechanisms that link and mutually in-
tensify the disorders.
Insulin	resistance
Insulin resistance is characterized by reduced responsiveness of 
insulin receptors and decreased downstream signaling for the 
purpose of insulin stimulation. To compensate for these dysfun-
ctions, the islet β-cells of the pancreas secrete more insulin, the-
reby creating a state of hyperinsulinemia. Insulin resistance 
with hyperinsulinemia constitutes the core feature of T2DM and 
is frequently also observed in AD patients.
Impaired insulin receptor signaling
There is evidence that Aβ oligomers can directly induce neuro-
nal insulin resistance in the AD brain by inhibiting the insulin 
signaling targeting the insulin/Akt pathway
38,39 and by remov-
ing insulin receptors after binding at the dendrites of synaptic 
sites.
40,41 Impaired insulin signaling cannot efficiently inhibit 
GSK3; therefore, the activated GSKα triggers APP γ-secretase 
activity, while the activated GSK3β increases tau phosphoryla-
tion,
42,43 which simultaneously aggravates the two major path-
ological substrates of AD. In addition, insulin signaling is im-
portant for the facilitation of memory via its regulation of sy-
naptic structure and functioning and its promotion of neuronal 
survival.
44 This effect is eliminated under conditions of imped-
ed insulin functioning, resulting in neurodegeneration.
When prolonged systemic hyperinsulinemia is combined 
with insulin resistance, insulin-related activities in the brain be-
come more impaired due to the decreased transport of insulin 
across the blood-brain barrier.
45 Furthermore, hyperinsulinemia 
in the peripheral blood supply is thought to raise CSF Aβ42 lev-
els.
46 Therefore, a pathological feed-forward relationship be-
tween insulin resistance and AD pathology operates in the pres-
ence of comorbid T2DM.
Impairment of Aβ clearance via IDEs
AD and T2DM share their major catalytic enzyme, IDE. As 
demonstrated in IDE
-/- animals,
27 deficiency in IDE increases 
Aβ and aggravates AD pathology in the brain, and the enhance-
ment of IDE activity reverses the exacerbated Aβ pathology in 
IDE
-/- and APP double-transgenic mice.
47 In states of hyperin-
sulinemia, increased insulin is more likely to efficiently bind to 
IDE than to Aβ; therefore, the level of native IDE that is avail-
able for binding to Aβ in the service of degradation markedly 
decreases, resulting in exacerbation of AD pathology. Postmor-
tem analyses of the brains of individuals with late-onset AD 
show decreased levels of IDE expression in the hippocampus,
48 
suggesting that the decreased availability of IDE is a common 
pathophysiology linking T2DM and AD.
Impaired	glucose	metabolism
T2DM inevitably results in chronic hyperglycemia, which im-
pairs glucose metabolism via ineffective glucose transport, de-
priving the neuronal cells of their major mechanism for metab-
olism and thereby producing serious complications that con-
tribute to AD pathology. In addition, decreased glucose meta-
bolism can be detected in AD even before the clinical onset of 
dementia, and is typically noted in fluorodeoxyglucose (FDG)- 
PET data. For this reason, FDG-PET can be a valuable neuro-
imaging marker for the early diagnosis of AD.
49
Decreased O-GlcNAcylation
Diminished O-GlcNAcylation is considered to be a major mo-
lecular mechanism through which impaired glucose metabolism 
confounds T2DM and AD. A rat model produced by i.c.v. injec-
tion of STZ
19 showed down-regulation of O-GlcNAcylation, 
impaired insulin signaling, and decreased glucose transporter 
activity. Decreased glucose metabolism in neurons lowers the 
level of UDP-GlcNAcylation, thereby decreasing tau O-Glc-
NAcylation. Decreased O-GlcNAcylation is also found in the 
brains of those with AD
50 and is inversely related to the phos-
phorylation of tau. Therefore, diminished O-GlcNAcylation 
may result in the hyperphosphorylation of tau, leading to the 
tau-related pathology associated with AD.
Increased	advanced	glycation	end	products,		
inflammation,	and	oxidative	stress
Chronic hyperglycemia induces the creation of advanced gly-
cation end products (AGEs) via Maillard reactions, during whi-
ch reducing sugars can react with the amino groups of proteins 
to produce cross-linked complexes and unstable compounds.
51 
Therefore, AGEs mediate various complications of diabetes by 
Table 3. Proposed common mechanisms linking AD and T2DM
Insulin resistance
Impaired insulin receptor signaling
Impairment of Aβ clearance via IDEs
Impaired glucose metabolism
Decreased O-GlcNAcylation
Advanced glycation end products, inflammation,  
  and oxidative stress
Enhanced glucocorticoid effect
Cerebrovascular insufficiency
Aβ: amyloid β protein, AD: Alzheimer’s disease, IDE: insulin-degrad-
ing enzyme, O-GlcNAcylation: O-linked N-acetylglucosamine gly-
cosylation, T2DM: type-2 DM.Type2 Diabetes and AD
16  J Clin Neurol 2011;7:10-18
interacting with the receptors for AGE present in the vascular 
cells and microglia, which enhances various inflammatory pro-
cesses and oxidative stress. Furthermore, increased AGEs can 
contribute to amyloidosis
52 and tau phosphorylation in AD.
53 
Indeed, the immunoreactivity of AGEs was markedly in-
creased in Aβ plaques and neurofibrillary tangles. Therefore, 
increased AGEs may be another important factor shared by 
T2DM and AD. On the other hand, increased inflammatory me-
diators such as tumor necrosis factor α, interleukin-1β, and in-
terleukin-6 are induced not only by AGEs, but also by hyperin-
sulinemia itself.
54 Specifically, the concentration of F2-iso-
prostane, a marker of lipid peroxidation, was increased in the 
CSF during insulin infusion in normal adults, and this was cor-
related with changes in CSF levels of Aβ42.
54 Increased levels 
of inflammatory cytokines along with oxidative stress derived 
from different mechanisms would be expected to lead to AD 
pathology through a synergistic process.
55
Enhanced	glucocorticoid	effect
In chronic uncontrolled DM, the concentration of circulating 
cortisol increases,
56,57 which adversely affects cognitive func-
tioning.
58 In db/db mice (the well-known T2DM model), enhan-
ced corticoid activity has been shown to result in impaired syn-
aptic plasticity and decreased neurogenesis, thereby yielding 
learning and memory deficits
59 and providing evidence that in-
creased cortisol contributes to the neurodegenerative complica-
tions of T2DM. With respect to AD, elevated levels of cortisol 
have been correlated with the extent of hippocampal atrophy, 
decreased cognitive performance, and rapid decline.
60,61 To-
gether these findings indicate that enhanced glucocorticoid ac-
tivity is a confounding factor in both T2DM and AD.
Cerebrovascular	insufficiency
T2DM increases cerebrovascular disease via an atherosclerotic 
process,
8,63 and data revealing the influence of cerebrovascular 
disease on the development and severity of AD have been re-
ported.
63 After excluding the influence of overt cerebrovascu-
lar disease, the intimate relationship between T2DM and AD 
persists, underpinned by the aforementioned common mecha-
nisms. Recent data obtained from ob/ob or polygenic NSY 
mice and from APP23 transgenic mice indicate that another 
pathology in the cerebral microvessels leading to cerebrovascu-
lar insufficiency constitutes a major contributor to the cognitive 
decline linked to both T2DM and AD.
35 Up-regulation of RAGE 
and inflammatory changes followed by increased amyloid de-
position in the cerebral small vessels have been shown to be im-
portant in producing cognitive impairments in these models, but 
not parenchymal Aβ burdens. Therefore, cerebrovascular insuf-
ficiency caused by increased RAGE-Aβ interactions, leading to 
inflammation and amyloid angiopathy, can be considered as a 
shared mechanism of T2DM and AD in addition to the overt 
cerebrovascular disorder resulting from increased vascular risk 
factors related to T2DM.
Conclusion
Animal models provide strong evidence of a relationship be-
tween T2DM and AD, and they suggest several potential mech-
anisms linking the two disorders. It is strongly suggested that 
AD pathology in T2DM derives from various mechanisms op-
erating synergistically rather than from a single mechanism op-
erating independently. Pathogenic alterations in insulin signal-
ing, Aβ clearance by IDE, glucose metabolism, O-GlcNA-
cylation, Aβ aggregation by AGEs, inflammation, oxidative 
stress, circulating cortisol, and cerebral vascular insufficiency 
are considered to contribute to both T2DM and AD. The inci-
dence of comorbidity of T2DM and AD increases with age. 
Therefore, this common pathophysiology probably constitutes 
a major underpinning of late-onset sporadic AD, and a novel 
therapeutic approach targeting this pathological process could 
contribute to the development of a more efficient and effective 
treatment for AD.
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